SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB
Authors:
- Gabriel KatzGKGabriel Katz
- Joseph MoisseievJMJoseph Moisseiev
- Anat LoewensteinALAnat Loewenstein
- Michaella GoldsteinMGMichaella Goldstein
- Yosef LomnickyYLYosef Lomnicky
- Yitzhak AbendYAYitzhak Abend
- Giora TreisterGTGiora Treister
- Dafna GoldenbergDGDafna Goldenberg
- Hana Levkovitch-VerbinHLHana Levkovitch-Verbin
- 1 July 2015
- journal article
- Published by Wolters Kluwer Health in Retina
- Vol. 35 (7) , 1323-1330
Abstract
To evaluate the safety and efficacy of switching from bevacizumab to ranibizumab in patients with neovascular age-related macular degeneration. Retrospective study of patients with neovascular age-related macular degeneration initially treated with bevacizumab and switched to ranibizumab. Visual acuity and central retinal thickness (CRT) were retrieved at four time points: before the last three bevacizumab injections, at the switch, after the first three ranibizumab injections, and at the end of follow-up. One hundred and fourteen eyes of 110 patients were included. Switching from bevacizumab to ranibizumab did not achieve a significant change in visual acuity, and a significant reduction in CRT was achieved after the first three injections but was not maintained by the end of follow-up. Eyes that lost ≥0.1 logMAR before the switch were more likely to improve in visual acuity (P = 0.013), and eyes with ≥10% increase in CRT before the switch were more likely to improve anatomically (P = 0.0003). In 47.3% of the eyes, the CRT was reduced by ≥10% after the first 3 ranibizumab injections, and the reduction was maintained with additional injections. Switching to ranibizumab should be considered in patients with visual acuity decrease or CRT increase, despite monthly bevacizumab injections. The response should be evaluated after the first three injections to guide future treatment.Keywords
This publication has 26 references indexed in Scilit:
- Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized TrialOphthalmology, 2013
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2013
- Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degenerationCurrent Opinion in Ophthalmology, 2009
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .JAMA, 2004
- Age-Related Macular Degeneration and Blindness due to Neovascular MaculopathyArchives of Ophthalmology (1950), 1984
- THE FRAMINGHAM EYE STUDYAmerican Journal of Epidemiology, 1977